Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 132 clinical trials
Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM) (HIRACOM)

The purpose of this study is to investigate the side effects, quality of life, and treatment effects of concurrent chemo-hypofractionated intensity-modulated radiation therapy in bladder cancer. Twenty fractionation within 4 weeks are performed using hypofractionated intensity-modulated radiation therapy. As for the radiation dose, 2.8-3.2 Gy at a time, total dose …

bladder tumor
metastasis
transurethral resection
carboplatin
invasive bladder cancer
  • 0 views
  • 24 Jul, 2022
  • 1 location
Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer (ABATE)

This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline cisplatin-based therapy. Each cycle equals 21 days. The dose of atezolizumab is 1200 mg IV flat dose every 3 weeks …

metastasis
bladder cancer
cancer
transurethral resection
radical cystectomy
  • 0 views
  • 23 Mar, 2022
  • 4 locations
Sacituzumab Govitecan, Preceding Radical Cystectomy, in Treating Patients With Muscle-invasive Bladder Cancer

primary objective of the study is to assess whether sacituzumab govitecan results in pathological complete response (in patients with Muscle-invasive Bladder Cancer who cannot receive or refuse cisplatin

irinotecan
radical cystectomy
bladder cancer
cancer
growth factor
  • 0 views
  • 14 Mar, 2022
  • 1 location
Trimodality Therapy With/Out Durvalumab to Treat Patients With Muscle-Invasive Bladder Cancer

The purpose of this study is to find out what effects durvalumab has on bladder cancer, combined with treatment after completion of surgery, chemotherapy and radiotherapy.

metastasis
bladder cancer
cancer
transurethral resection
mitomycin
  • 47 views
  • 28 Jun, 2022
  • 39 locations
Intravesical Gemcitabine and Docetaxel for BCG na ve Non-muscle Invasive Bladder Cancer

invasive bladder cancer (NMIBC). All participants will receive an induction course of gemcitabine/docetaxel instillations followed by maintenance instillations if initial efficacy is seen. In addition to

carcinoma in situ
bcg vaccine
bladder cancer
cancer
transurethral resection
  • 2 views
  • 17 Sep, 2021
  • 1 location
18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy

This research study is studying a positron emission tomography (PET) agent called 18F-fluciclovine to evaluate how well 18F-fluciclovine-PET scans determine the extent of muscle invasive bladder

metastasis
bladder cancer
cancer
ct scan
radical cystectomy
  • 1 views
  • 18 Apr, 2022
  • 1 location
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

The purpose of this study is to assess the effectiveness of erdafitinib in people with non-muscle invasive bladder cancer (NMIBC) that has come back after standard treatment, such as Bacillus

mitomycin
transurethral resection
invasive bladder cancer
bladder tumor
intravesical chemotherapy
  • 0 views
  • 10 May, 2022
  • 7 locations
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy

systemic therapy
antibiotics
autoimmune disease
hepatitis b
transurethral resection
  • 42 views
  • 09 Aug, 2022
  • 184 locations
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer

This is a Phase II, single-arm, study of pembrolizumab as maintenance therapy in muscle-invasive bladder cancer (MIBC) participants who have received maximum TURBT and tri-modality treatment

measurable disease
pembrolizumab
bladder tumor
carcinoma
invasive bladder cancer
  • 0 views
  • 22 Mar, 2022
  • 1 location
Nivolumab Plus Chemoradiotherapy in Patients With Muscle-invasive Bladder Cancer (MIBC) Not Undergoing Cystectomy

The purpose of this study is to investigate the effect synchronous use of nivolumab in addition to chemoradiotherapy in patients withnon-metastatic MIBC who are not candidates for radical cystectomy

radical cystectomy
bladder cancer
cancer
nivolumab
invasive bladder cancer
  • 9 views
  • 13 Apr, 2022
  • 1 location